R&D,Bioprocess,Clinical Development,Weekly Roundups

Weekly News Round-up – 17/7/20

5 months ago By Josh Neil
  • Share on

  • Facebook
  • Linkedin
Proventa International Weekly News

In the news this week, despite significant alarms recently that GSK’s belantamab mafodotin could endanger patients’ eyes, the multiple myeloma drug has been approved by expert advisers. In other news, Novartis promises to make no profit from 15 of its COVID drugs sent to developing countries; and J&J is set to begin human testing of its own COVID-19 drug.

GSK’S MULTIPLE MYELOMA DRUG FDA-APPROVED DESPITE SAFETY FEARS – Despite FDA concerns around danger to patients’ eyes, GSK’s first-in-class multiple myeloma drug belantamab mafodotin has been backed by a panel of FDA expert advisers. The drug is expected to The regulatory is expected to come to a final decision in the next few weeks. 

ROCHE AND BLUEPRINT SIGN $1.7 BILLION DEAL ON CANCER DRUG – Roche and cancer drug company Blueprint have signed a deal worth up to $1.7 billion over pralsetinib, a drug targeting tumours with RET mutations. The two companies will equally market the drug and share profits and losses in the U.S. This deal will see Roche come into competition with Eli Lilly, whose RET inhibitor is already approved by the FDA. 

NOVARTIS PROMISES TO MAKE NO PROFIT FROM 15 COVID DRUGS IN POOR COUNTRIES – Novartis’s Sandoz unit has promised to offer 15 generic and over-the-counter medicines for no profit to developing countries while the COVID-19 pandemic continues. The range of drugs will cover cardiovascular and gastrointestinal diseases, and in particular dexamethasone, which has shown to cut death rates in severely ill coronavirus patients. 

In other news:

Clinical Trials
Bayer/Merck’s heart failure drug vericiguat receives FDA fast review
J&J to begin human testing of COVID-19 drug

Manufacturing
Moderna begins production of COVID vaccine for at-risk patients
FDA reveals plans for restarting domestic inspections

That’s all for now. See you next week!

Joshua Neil, Editor
Proventa International

To ensure you remain up-to-date on the latest in clinical development, sign up for Proventa International’s online Clinical Operations, Supply Chain & Pharmacovigilance Strategy Meeting 2020.

More news

How COVID-19 has Affected Clinical Operations

The COVID-19 pandemic has disrupted sectors and organisations around the world. But one of the most vital fields that has seen significant impact is in clinical operations. Trials and supply chains have had to be rapidly changed to accommodate the...

2 months ago
R&D,Bioprocess,Clinical Development,Weekly Roundups

How COVID-19 has Affected Clinical Operations

The COVID-19 pandemic has disrupted sectors and organisations around the world. But one of the most vital fields that has seen significant impact is in clinical operations. Trials and supply chains have had to be rapidly changed to accommodate the...

2 months ago

Better CMC Organisation in Small Pharma Drug Development

Chemistry, Manufacturing and Controls (CMC) is a vital part of the drug development process. A CMC strategy gives companies a template for bringing a drug through the early clinical stages all the way to commercial manufacturing.  The CMC process has...

2 months ago
R&D,Bioprocess,Clinical Development,Weekly Roundups

Better CMC Organisation in Small Pharma Drug Development

Chemistry, Manufacturing and Controls (CMC) is a vital part of the drug development process. A CMC strategy gives companies a template for bringing a drug through the early clinical stages all the way to commercial manufacturing.  The CMC process has...

2 months ago

Solving Regulatory Issues in Cell and Gene Therapies

Cell and Gene Therapies (CGTs), experimental technologies to treat or cure diseases using the body’s cells, have been on the ascendant for some time now. As promising as they are, CGTs have consistently moved forward faster than regulatory agencies can...

2 months ago
R&D,Bioprocess,Clinical Development,Weekly Roundups

Solving Regulatory Issues in Cell and Gene Therapies

Cell and Gene Therapies (CGTs), experimental technologies to treat or cure diseases using the body’s cells, have been on the ascendant for some time now. As promising as they are, CGTs have consistently moved forward faster than regulatory agencies can...

2 months ago
Working With us

Interested?
Reserve your space